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Abstract
Background: High D-dimer (DD) is associated with short-term adverse outcomes in patients with 
acute coronary syndrome (ACS). In ACS patients who underwent percutaneous coronary intervention 
(PCI), however, the value of DD (or combined with neutrophil to lymphocyte ratio [NLR]) to predict 
long-term major adverse cardiovascular events (MACEs) has not been fully evaluated. 
Methods: Patients diagnosed with ACS and receiving PCI were included. The primary outcome was 
MACEs. Cox proportional hazards regression and logistic regression were used to illustrate the relation-
ship between clinical risk factors, biomarkers and MACEs. Survival models were developed based on 
significant factors and evaluated by the Concordance-index (C-index).
Results: The final study cohort was comprised of 650 patients (median age, 64 years; 474 males), 
including 98 (15%) with MACEs during a median follow-up period of 40 months. According to the 
cut-off value of DD and NLR, the patients were separated into four groups: high DD or nonhigh DD 
with high or nonhigh NLR. After adjusting for confounding variables, DD (adjusted hazard ratio 
[aHR]: 2.39, 95% confidence interval [CI]: 1.52–3.76) and NLR (aHR: 2.71, 95% CI: 1.78–4.11) were 
independently associated with long-term MACEs. Moreover, patients with both high DD and NLR had  
a significantly higher risk in MACEs when considering patients with nonhigh DD and NLR as reference 
(aHR: 6.19, 95% CI: 3.30–11.61). The area under curve increased and reached 0.70 in differentiating  
long-term MACEs when DD and NLR were combined, and survival models incorporating the two 
exhibited a stronger predictive power (C-index: 0.75). 
Conclusions: D-dimer (or combined with NLR) can be used to predict long-term MACEs in ACS 
patients undergoing PCI. (Cardiol J)
Key words: acute coronary syndrome, D-dimer, neutrophil to lymphocyte ratio,  
long-term outcome, percutaneous coronary intervention
Introduction
Coronary heart disease (CHD) is one of the 
leading causes of death worldwide [1]. Acute coro-
nary syndrome (ACS) is an acute manifestation of 
CHD, including ST-segment elevation myocardial 
infarction (STEMI), non-ST-segment elevation 
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angina, which has a higher risk of morbidity, re-
hospitalization, and mortality. Thus, adequate risk 
assessments are essential for patients with ACS.
D-dimer (DD) is a fibrin degradation product 
during the process of fibrinolysis, and is often used 
as a marker for hypercoagulation and thrombus 
formation. Many diseases present with elevated 
DD, such as venous thromboembolism, acute aortic 
dissection and peripheral artery disease. Recently, 
it has been discovered that the above-mentioned 
diseases may not be the only scenarios where 
DD can be used. Studies revealed that baseline 
DD can be utilized as a predictive biomarker for 
cardiovascular outcomes in patients with stable 
CHD and ACS [2, 3]. However, its clinical efficacy 
in long-term cardiovascular outcomes has not yet 
been fully assessed in patients with ACS receiving 
percutaneous coronary intervention (PCI). 
Atherosclerosis is an inflammatory disease 
and it plays a dominant role in ACS [4, 5]. Lately, 
inflammatory biomarkers such as neutrophil to 
lymphocyte ratio (NLR) have emerged to be eas-
ily accessible, cost-effective indicators in various 
cardiovascular disorders including stable CHD, 
heart failure and ACS [6–10]. Previous studies have 
shown that NLR was an independent predictor of 
major adverse cardiovascular events (MACEs) in 
patients with ACS [7, 8]. 
This study tried to evaluate the long-term 
prognostic value of DD alone and in combination 
with NLR for MACEs in patients with ACS who 
underwent PCI.
Methods
Study design and population
This was a retrospective longitudinal cohort 
study which included 792 consecutive patients 
who were diagnosed as ACS at the Department 
of Cardiology, First Affiliated Hospital of Nanjing 
Medical University between February 2016 and 
December 2016. 
Acute coronary syndrome was subdivided into 
STEMI, NSTEMI and unstable angina, and the 
diagnostic criteria were as follows. STEMI was 
considered in the presence of (1) at least two con-
tiguous leads with ST-segment elevation ≥ 2 mm 
in chest leads and/or ST-segment elevation of 
≥ 1 mm in the other leads or new left bundle branch 
block (LBBB) and (2) a detection of a dynamic 
change of cardiac troponin T with at least one value 
above the 99th percentile upper reference limit 
[11, 12]. If electrocardiograph revealed diagnostic 
ischemia patterns without persistent ST-elevation 
as well as cardiac markers were elevated, patients 
were considered to have NSTEMI. Those who had 
typical chest pain and cardiac markers within the 
normal range were deemed to have unstable angina 
[13]. All three main coronary arteries (left anterior 
descending coronary artery and/or collateral, left 
circumflex coronary artery and/or collateral, right 
coronary artery and/or collateral) had at least 
one stenosis (diameter stenosis determined by 
angiography ≥ 50%), with or without the left main 
artery involvement was considered to be a three-
-vessel or left main disease. Other definitions in 
the present study including hypertension, diabetes, 
dyslipidemia, smoking and drinking were based on 
currently accepted criteria.
The inclusion criteria were: (1) adult patients 
(age older than 18 years), (2) clinically diagnosed 
as ACS and underwent PCI. The exclusion criteria 
were as follows: (1) patients were on anticoagu-
lant or steroid therapy at admission (10 cases), 
(2) patients had active inflammation at admission 
(defined as T ≥ 38.5°C and at least one typical 
symptom, e.g. cough, sneezing or vomiting) or 
experienced vascular thromboembolism within 
6 months (24 cases), (3) patients with comorbidities, 
including hematological disorders, uncontrolled 
chronic inflammation disease, malignant tumors, 
severe hepatic disease or renal disease (alanine 
aminotransferase > 400 U/L or estimated glomeru-
lar filtration rate [eGFR] < 30 mL/min/1.73 m2) 
(50 cases), (4) blood cell count or DD not collected 
before PCI (5 cases). Due to follow-up data for 
53 (7.5%) patients were not available, a total of 
650 patients were included in the final cohort for 
analysis.
Medical variables collection
Patients’ gender, age, body mass index (BMI), 
admission and discharge date, smoking, drinking 
history, hypertension, diabetes, and laboratory 
measurements, procedural details and medications 
at discharge were collected. Information of these 
variables was obtained from the hospital informa-
tion system or by contacting patients or their family 
members.
Laboratory tests 
Venous blood samples were obtained within 
24 h before the initial treatment for blood analysis. 
Whole blood cell counts including leucocytes, neu-
trophils, lymphocytes, hemoglobin and platelets 
were measured using the XE-5000 fully-autonomic 
hematology analyzer (Sysmex, Kobe, Japan). NLR 
was calculated by dividing the neutrophil count 
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by the lymphocyte count. Biochemical indicators 
including total cholesterol, triglycerides, low-den-
sity lipoprotein cholesterol (LDL-C), high-density 
lipoprotein cholesterol (HDL-C), liver and renal 
function, cardiac troponin T were determined using 
an automatic biochemistry analyzer (Bayer ADVIA 
1650, Siemens, Wilmington, DE, USA). Plasma DD 
was carried out by immunoturbidimetric assay us-
ing a coagulation analyzer (Diamed CDX, Diamond 
Diagnostics, Holliston, USA).
Clinical follow-up and outcomes
Follow-up was performed by trained coordi-
nators through telephone interviews or review 
of medical records. The primary outcomes of this 
study were the occurrence of MACEs, includ-
ing all-cause mortality, cardiac death, myocardial 
infarction (MI), target vessel revascularization 
(TVR) and stroke during follow-up. Cardiac death 
was defined as any death caused by cardiac prob-
lems. MI was defined based on the fourth universal 
definition of MI [11]. Stroke was defined as sud-
denly developed sensory and motor dysfunction 
resulting from brain abnormalities, or imaging 
studies revealed evidences of brain infarction or 
hemorrhage related to the symptoms [14]. TVR 
was defined as any repeat intervention of upstream 
and downstream branches of the target vessel and 
itself as recommended by the Academic Research 
Consortium [15].
Ethical approval
This study protocol was approved by the 
Ethics Committee of First Affiliated Hospital of 
Nanjing Medical University. The need for informed 
consent from patients was waived because of the 
retrospective study design. 
Statistical analysis
Continuous variables were expressed as me-
dian and interquartile range (IQR). Categorical 
variables were expressed as numbers (percent-
ages). Continuous variables were compared using 
the Mann-Whitney U test or Kruskal-Wallis H 
test as appropriate and categorical variables were 
compared using the chi-square (c2) test or the 
Fisher exact test. 
Receiver operating characteristic (ROC) 
curves were plotted to calculate the area under 
curves (AUC), cut-off values, sensitivities, and 
specificities of DD and NLR. In accordance with 
the optimal cut-off values of DD (0.31 µg/mL) and 
NLR (3.31), patients were divided into four groups: 
nonhigh DD and nonhigh NLR (DD–/NLR–), non-
high DD and high NLR (DD–/NLR+), high DD 
and nonhigh NLR (DD+/NLR–), and high DD and 
high NLR (DD+/NLR+). The Delong test (AUC 
comparison), net reclassification index (NRI), and 
integrated discrimination index (IDI) were evalu-
ated for model discrimination.
To identify and evaluate the independent pre-
dictors of MACEs, univariate and multivariate Cox 
proportional hazards analyses were obtained. Vari-
ables including age, gender, BMI, comorbidities, 
known medical history, biomarkers, medications 
and procedural data were adjusted in this model. 
Logistic regression was also conducted to validate 
the independent predictive factors of MACEs. 
Different survival models were developed basing 
on identified variables predictive for MACEs. The 
Concordance index (C-index) was calculated to 
evaluate the discriminative ability of each model. 
The p value from the likelihood-ratio test was used 
for comparison of different models. The results of 
the risk analyses were provided as hazard ratios 
with 95% confidence interval (CI) and the results 
of logistic regression were shown as the odds ratio 
and 95% CI. P value < 0.05 (two-tailed) was consid-
ered statistically significant. Statistical analysis was 
performed using IBM SPSS 24.0 software package 
(SPSS Inc., Chicago, Illinois, USA) and GraphPad 
Prism version 8.0.0 for Windows (GraphPad Soft-
ware, San Diego, California USA).
Results
Baseline clinical characteristics
A total of 792 patients were screened, of whom 
650 patients met the criteria for enrollment (Fig. 1). 
The clinical characteristics of the entire study co-
hort are summarized in Table 1. The median age 
of the study cohort was 64 years, and 73% were 
male. Among all patients, 68% had hypertension, 
22% had diabetes and 5% had a history of PCI. 
Compared to the MACEs-free group, the patients 
in the MACEs group were older, had higher levels 
of DD, NLR, leucocytes, neutrophils, peak cardiac 
troponin T, and a higher proportion of three-vessel 
or left main disease. They also presented with 
lower levels of lymphocytes, eGFR, and had poorer 
ejection fraction (EF). 
Patients with higher levels of DD and NLR 
tended to have worse prognoses. ROC curves were 
then used to determine the cut-off values of DD and 
NLR, and patients were divided into four groups 
according to the levels of DD and NLR for further 
analysis. Table 2 shows that patients in the high DD 
groups were more likely to be elderly, had lower 
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792 patients diagnosed as ACS
and received PCI were screened






— 10 anticoagulant or steroid therapy at admission
— 24 active inammation at admission or vascular thromboembolism
     within 6 months
— 50 hematological disorders, uncontrolled chronic inammation
     disease, malignant tumors, severe hepatic disease or renal disease
— 5 blood cell count or D-dimer not collected before PCI
53 (7.5%) no follow-up data available
703 ACS patients receiving PCI included in the study
650 eligible ACS patients receiving PCI enrolled in the nal analysis
Figure 1. Flow chart of patient inclusion; ACS — acute coronary syndrome; PCI — percutaneous coronary interven-
tion; MACEs — major adverse cardiovascular events.
Table 1. Comparison of baseline characteristics between patients with major adverse cardiovascular 
events (MACEs)-free and MACEs groups.







Age [years] 64 (56–71) 63 (55–70) 67 (61–75) < 0.001
Gender, Male 474 (72.9%) 398 (72.1%) 76 (77.6%) 0.263
BMI [kg/m2] 24.7 (22.9–26.6) 24.8 (22.9–26.6) 24.1 (22.9–26.1) 0.108
Hypertension 440 (67.7%) 373 (67.6%) 67 (68.4%) 0.877
Diabetes mellitus 161(21.8%) 140 (25.4%) 21 (21.4%) 0.406
Dyslipidemia 449 (69.1%) 80(70.2%) 69 (70.4%) 0.757
Smoking 236 (36.3%) 199 (36.1%) 37 (37.8%) 0.746
Drinking 108 (16.6%) 94 (17.0%) 14 (14.3%) 0.501
Previous PCI 32 (4.9%) 26 (4.7%) 6 (6.1%) 0.610
Laboratory parameters
Leucocyte [109/L] 6.77 (5.63–8.93) 6.67 (5.58–8.57) 7.47 (5.78–11.26) 0.003
Neutrophil [109/L] 4.47 (3.36–6.19) 4.32 (3.32–5.80) 5.39 (3.71–8.76) < 0.001
Lymphocyte [109/L] 1.70 (1.30–2.13) 1.74 (1.34–2.15) 1.49 (1.07–1.98) < 0.001
NLR 2.46 (1.82–3.96) 2.36 (1.80–3.53) 3.92 (2.10–6.83) < 0.001
D-dimer [µg/mL] 0.24 (0.14–0.42) 0.22 (0.14–0.38) 0.37 (0.23–0.83) < 0.001
Total cholesterol [mmol/L] 4.20 (3.52–4.99) 4.17 (3.50–5.01) 4.35 (3.60–4.95) 0.547
Triglycerides [mmol/L] 1.32 (1.00–1.76) 1.33 (0.99–1.78) 1.32 (1.01–1.66) 0.926
LDL-C [mmol/L] 2.71 (2.20–3.25) 2.69 (2.17–3.25) 2.80 (2.28–3.32) 0.364
HDL-C [mmol/L] 1.01 (0.87–1.19) 1.02 (0.87–1.19) 0.95 (0.86–1.19) 0.146
eGFR [mL/min/1.73 m2] 93.00 (83.00–100.00) 93.00 (84.00–101.00) 89.00 (76.75–99.00) 0.012







Ejection fraction [%] 63.00 (60.10–65.40) 63.30 (60.90–65.60) 61.95 (51.75–64.00) < 0.001
Æ
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Table 1 (cont.). Comparison of baseline characteristics between patients with major adverse cardio-
vascular events (MACEs)-free and MACEs groups.








Antiplatelet 647 (99.5%) 550 (99.6%) 97 (99.0%) 0.388
Antihypertensive 542 (83.4%) 461(83.5%) 81 (82.7%) 0.833
Lipid-lowering medications 642 (98.8%) 546 (98.9%) 96 (98.0%) 0.345
Procedural data
Vessel treated:
LM 10 (1.5%) 6 (1.1%) 4 (4.1%) 0.049
LAD 449 (69.1%) 386 (69.9%) 63 (64.3%) 0.265
LCX 210 (32.3%) 175 (31.7%) 35 (35.7%) 0.434
RCA 257 (39.5%) 215 (38.9%) 42 (42.9%) 0.466
Three-vessel or left main 296 (45.5%) 240 (43.5%) 56 (57.1%) 0.012
Number of implanted stents 2.00 (1.00–2.00) 2.00 (1.00–2.00) 2.00 (1.00–3.00) 0.097
Total stent length [mm] 40.50 (24.75–60.00) 39.00 (24.00–59.00) 48.00 (25.00–66.00) 0.052
Total stent diameter [mm] 5.25 (3.00–7.25) 5.25 (3.00–7.00) 5.75 (3.00–7.75) 0.399
Data are median (interquartile range) or number (%). BMI — body mass index; cTnT — cardiac troponin T; eGFR, — estimated glomerular 
filtration rate; HDL-C — high-density lipoprotein cholesterol; LAD — left anterior descending coronary artery; LCX — left circumflex coronary 
artery; LDL-C — low-density lipoprotein cholesterol; LM — left main coronary artery; MACEs — major adverse cardiovascular events;  
NLR — neutrophil to lymphocyte ratio; PCI — percutaneous coronary intervention; RCA — right coronary artery
Table 2. Characteristics in the four groups according to the cut-off values of D-dimer and NLR.









Age [years] 61 (53–67) 62 (53–71) 69 (62–75) 69 (61–78) < 0.001
Male 211 (70.3%) 101 (88.6%) 92 (65.2%) 70 (73.7%) < 0.001
BMI [kg/m2] 24.8 (22.9–26.7) 24.6 (23.0–26.5) 24.6 (22.7–26.7) 24.2 (22.7–26.4) 0.459
Hypertension 197 (65.7) 82 (71.9) 100 (70.9) 61 (64.2) 0.441
Diabetes mellitus 71 (23.7%) 18 (15.8%) 48 (34%) 24 (25.3%) 0.009
Dyslipidemia 213 (71.0%) 80 (70.2%) 99 (70.2%) 57 (60.0%) 0.228
Smoking 107 (35.7%) 51 (44.7%) 44 (31.2%) 34 (35.8%) 0.161
Drinking 60 (20.0%) 18 (15.8%) 18 (12.8%) 12 (12.6%) 0.162
Previous PCI 13 (4.3%) 4 (3.5%) 8 (5.8%) 7 (7.4%) 0.527
Laboratory parameters
Leukocyte [109/L] 6.30 (5.28–7.52) 9.56 (7.03–11.37) 6.03 (4.92–7.43) 9.13 (6.94–12.22) < 0.001
Neutrophil [109/L] 3.88 (2.97–4.72) 7.49 (5.28–9.37) 3.68 (2.90–4.56) 7.04 (5.45–10.39) < 0.001
Lymphocyte [109/L] 1.90 (1.59–2.31) 1.30 (0.99–1.69) 1.85 (1.49–2.23) 1.21 (1.01–1.47) < 0.001
NLR 2.04 (1.55–2.50) 5.45 (4.02–8.17) 2.08 (1.60–2.45) 5.48 (4.06–8.17) < 0.001
D-dimer [µg/mL] 0.17 (0.11–0.23) 0.16 (0.11–0.23) 0.51 (0.37–0.81) 0.62 (0.45–1.24) < 0.001
Total cholesterol [mmol/L] 4.10 (3.45–4.96) 4.34 (3.55–5.13) 4.14 (3.40–4.88) 4.41 (3.69–5.12) 0.085
Triglycerides (mmol/L] 1.36 (1.00–1.99) 1.20 (0.99–1.65) 1.32 (1.01–1.66) 1.31 (0.90–1.65) 0.174
LDL-C [mmol/L] 2.65 (2.09–3.21) 2.83 (2.22–3.48) 2.72 (2.16–3.25) 2.73 (2.28–3.47) 0.106
HDL-C [mmol/L] 1.01 (0.86–1.19) 1.02 (0.87–1.17) 1.00 (0.84–1.20) 1.06 (0.92–1.23) 0.242
eGFR [mL/min/1.73 m2] 96.0 (88.0–102.0) 95.0 (85.0–101.50) 85.0 (76.0–95.0) 87.0 (75.0–98.0) < 0.001
Peak cTnT [ng/L] 10 (5–43) 1375 (125–4495) 15 (8–157) 1926 (74–4982) < 0.001
Ejection fraction [%] 64.0 (62.0–65.9) 62.05 (56.0–65.5) 62.1 (60.0–64.4) 60.9 (51.0–63.7) < 0.001
Æ
www.cardiologyjournal.org 5
Ling-Feng Gu et al., Prognostic value of combined D-dimer level and NLR in ACS patients
EF, eGFR, an increased proportion of three-vessel 
or left main disease and longer total stent length. 
There were no significant differences among four 
groups in terms of BMI, hypertension, dyslipi-
demia, current smoking, drinking, previous PCI, 
total cholesterol, triglycerides, LDL-C, HDL-C, 
and discharge medication.
Clinical outcomes
During a median follow-up duration of 40 
months (IQR: 37–43), the MACEs occurred in 
98 (15.1%) patients: 28 events of all-cause death, 
12 events of stroke, 10 MIs, and 56 TVRs. Specifi-
cally, MACEs occurred in 47 (25.0%) out of 188 
STEMI patients, 10 (19.2%) out of 52 NSTEMI 
patients, and 41 (10%) out of 410 unstable angina 
patients. The MACEs rates were similar between 
the first two, and both were higher than the last 
one. The MACEs rates among four groups are 
presented in Table 3. Patients in DD–/NLR– group 
had the lowest incidence of MACEs (5.3%), and 
those in DD+/NLR+ group had the highest 
(41.1%). Moreover, patients with both high DD 
and NLR levels had significantly higher rates of 
all-cause mortality, cardiac death, MI, TVR and 
stroke than the other three groups. 














MACEs 98 (15.1%) 16 (5.3%) 19 (16.7%) 24 (17.0%) 39 (41.1%) < 0.001
All-cause mortality 28 (4.3%) 1 (0.3%) 3 (2.6%) 9 (6.4%) 15 (15.8%) < 0.001
Cardiac death 19 (2.9%) 0 (0%) 3 (2.6%) 7 (5.0%) 9 (9.5%) < 0.001
MI 10 (1.5%) 0 (0%) 3 (2.6%) 2 (1.4%) 5 (5.3%) 0.001
TVR 56 (8.6%) 14 (4.7%) 14 (12.3%) 13 (9.2%) 15 (15.8%) 0.003
Stroke 12 (1.8%) 1 (0.3%) 2 (1.8%) 2 (1.4%) 7 (7.4%) 0.001
DD — D-dimer; MACEs — major adverse cardiovascular events; MI — myocardial infarction; NLR — neutrophil to lymphocyte ratio;  
TVR — target vessel revascularization
Table 2 (cont.). Characteristics in the four groups according to the cut-off values of D-dimer and NLR.










Antiplatelet 299 (99.7%) 113 (99.1%) 140 (99.3%) 95(100.0%) 0.749
Antihypertensive 251 (83.7%) 97 (85.1%) 120 (85.1%) 74 (77.9%) 0.453
Lipid-lowering medications 298 (99.3%) 112 (98.2%) 137 (97.2%) 95 (100.0%) 0.140
Procedural data
Vessel treated:
LM 3 (1.0%) 1 (0.9%) 4 (2.8%) 2 (2.1%) 0.397
LAD 203 (67.7%) 77 (67.5%) 101 (71.6%) 68 (71.6%) 0.774
LCX 97 (32.3%) 36 (31.6%) 45 (31.9%) 32 (33.7%) 0.989
RCA 112 (37.3%) 49 (43.0%) 53 (37.6%) 43 (45.3%) 0.440
Three-vessel or left main 126 (42.0%) 50 (43.9%) 72 (51.1%) 48 (50.5%) 0.228
Number of implanted stents 2 (1–2) 2 (1–2) 2 (1–3) 2 (1–3) 0.046


















Data are median (interquartile range) or number (%). BMI — body mass index; cTnT — cardiac troponin T; DD — D-dimer; eGFR — estimated 
glomerular filtration rate; HDL-C — high-density lipoprotein cholesterol; LAD — left anterior descending coronary artery; LCX — left circumflex 
coronary artery; LDL-C — low-density lipoprotein cholesterol; LM — left main coronary artery; NLR — neutrophil to lymphocyte ratio;  
PCI — percutaneous coronary intervention; RCA — right coronary artery
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Association between baseline  
DD, NLR levels and MACEs
To demonstrate the association of baseline DD 
and NLR levels with MACEs risk, Kaplan-Meier 
survival curves and Cox regression analyses were 
performed. Univariate Cox regression analyses 
showed that age (per 10-year increase), BMI, 
leucocyte, neutrophil, lymphocyte, NLR, DD (per 
0.1 µg/mL increase), HDL-C, eGFR (per 10 mL/ 
/min/1.73 m2 increase), log peak cardiac troponin T, 
EF (per 10% increase) and three-vessel or left 
main disease were predictors for the endpoint of 
MACEs (p < 0.15). Then, further multivariate Cox 
analysis revealed that age (per 10-year increase), 
NLR, DD (per 0.1 µg/mL increase), HDL-C and 
EF (per 10% increase) were independently and 
significantly associated with MACEs. The same 
results were obtained using the logistic regression 
(Suppl. Tables 1, 2). 
Four different survival models were then built 
according to the above-mentioned significant fac-
tors. Model 1 was developed based on age (per 
10-year increase), HDL-C, EF (per 10% increase). 
Model 2A and 2B added DD and NLR on the ba-
sis of model 1, respectively. Model 3 added the 
combination of DD and NLR (with DD–/NLR– as 
reference) on the basis of model 1. After adjusting 
for variables in model 2A and 2B, 1.4 times and 1.7 
times higher risk of MACEs were still observed in 
elevated levels of DD (adjusted hazard ratio [aHR]: 
2.39, 95% CI: 1.52–3.76, p < 0.001) and elevated 
levels of NLR (aHR: 2.71, 95% CI: 1.78–4.11, 
p < 0.001) (Suppl. Fig. 1A, B; Table 4). Further-
more, in model 3, patients in the DD+/NLR+ 
group were found to have a significantly higher risk 
in MACEs than with patients in the DD–/NLR– 
group as reference (aHR: 6.19, 95% CI: 3.30–11.61, 
p < 0.001) (Fig. 2, Table 4). 
Comparison of predictive efficacy  
of DD and NLR for MACEs
Receiver operating characteristic curves were 
used to evaluate the predictive efficacy of DD, NLR 
and the combination of DD and NLR (Fig. 3). The 
AUC of DD to predict MACEs was 0.68 (95% CI: 
0.62–0.73, p < 0.001) together with a sensitivity of 
64.3% and a specificity of 68.7%. NLR had an AUC 
of 0.66 (95% CI: 0.59–0.72, p < 0.001) together 
with a sensitivity of 59.2% and a specificity of 
72.6%. The combination of DD and NLR achieved 
the largest AUC (AUC: 0.70, 95% CI: 0.64–0.76, 
p < 0.001) in predicting long-term MACEs than 
DD and NLR alone. The Delong test for comparison 
of ROC curves revealed that DD had a comparable 
value with NLR (p = 0.704). Compared with NLR 
alone, adding DD to NLR resulted in a statistically 
significant improvement in risk discrimination 
(AUC) and a nearly significant improvement in 
reclassification (NRI, IDI) (p = 0.008; NRI 4.9%, 
p = 0.11; IDI 1.6%, p = 0.08). There was no sig-
nificant difference in AUC between adding NLR 
to DD and DD alone, but reclassification shows 
significant improvement (p = 0.560; NRI 17.0%, 
p < 0.001; IDI 5.0%, p < 0.001).
Comparison of survival models
The inclusion of DD and NLR in model 2A and 
2B increased the C-index from 0.678 to 0.724 and 
0.726, respectively (likelihood-ratio test p < 0.001 
for both), indicating a significant improvement 
compared to model 1. The C-index for model 3 was 
0.750, revealing a better fit than model 1, 2A and 
2B (all p < 0.001).
Discussion
Considering the large number of ACS patients 
worldwide and the threat to their lives, how to 
choose low-cost, easy-to-operate, and repeat-
able clinical indicators to predict the prognosis of 
Figure 2. The Kaplan-Meier survival curves according 
to the combination of D-dimer (DD) and neutrophil to 
lymphocyte ratio (NLR) in patients with acute coronary 
syndrome undergoing percutaneous coronary interven-
tion. The median follow-up period was 40 months. For 
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patients has been a long-standing problem. In the 
present study, we explored predictive factors and 
developed models based on DD and NLR to predict 
MACEs for ACS patients undergoing PCI.
Here, five factors were identified including 
age, DD, NLR, HDL-C and EF, were associated 
with MACEs in ACS patients.
Hypercoagulability is the driving factor of 
atherosclerosis [16], and thrombosis is a further 
important mechanism for the initiation and de-
velopment of atherosclerosis and ACS [17]. DD, 
a degradation product of fibrin molecules, reflects 
the degree of hypercoagulation and thrombotic 
activity in the body simultaneously. The LIPID 
study, which included 7863 patients and up to 16 
years of follow-up showed that high baseline DD 
indicated poor prognoses for all-cause mortal-
ity and cardiovascular mortality in patients with 
stable CHD [2]. Akgul et al. [18] found that high 
DD at admission was an independent predictor 
of in-hospital and 6-month all-cause mortality in 
STEMI patients receiving primary PCI. AlKhalfan 
et al. [3] demonstrated that elevated baseline DD 
was associated with an increased risk of cardiac 
death, MI, and stroke in patients with ACS, but the 
median follow-up time of their study was signifi-
cantly shorter than the present study (6 months 
vs. 40 months). In another prospective observa-
tional study, patients with suspected ACS were 
followed up for 7 years, finding that high levels 
of DD were associated with all-cause mortality. 
However, nearly half of the patients were finally 
determined to be non-ACS, and only 20% of the 
patients received PCI or coronary artery bypass 
grafting treatment [19]. Thus, according to avail-
able research, this is the first study to show that 
DD levels can predict long-term MACEs for ACS 
patients undergoing PCI. 
Table 4. Different models of major adverse cardiovascular events by multivariate Cox regression  
analyses.
Variable Crude Adjusted*
HR 95% CI P HR 95% CI P
Model 1
Age (per 10-year increase) 1.52 1.25–1.85 < 0.001 1.33 1.05–1.68 0.017
HDL-C 0.53 0.23–1.24 0.145 0.34 0.14–0.85 0.021
EF (per 10% increase) 0.51 0.42–0.63 < 0.001 0.64 0.50–0.82 < 0.001
Model 2A
Age (per 10-year increase) 1.52 1.25–1.85 < 0.001 1.26 1.03–1.53 0.022
HDL-C 0.53 0.23–1.24 0.145 0.48 0.21–1.11 0.086
EF (per 10% increase) 0.51 0.42–0.63 < 0.001 0.59 0.48–0.74 < 0.001
DD– Ref – – Ref – –
DD+ 3.47 2.30–5.25 < 0.001 2.39 1.52–3.76 < 0.001
Model 2B
Age (per 10-year increase) 1.52 1.25–1.85 <0.001 1.39 1.16–1.68 < 0.001
HDL-C 0.53 0.23–1.24 0.145 0.39 0.16–0.92 0.031
EF (per 10% increase) 0.51 0.42–0.63 < 0.001 0.61 0.49–0.76 < 0.001
NLR– Ref – – Ref – –
NLR+ 3.39 2.26–5.07 < 0.001 2.71 1.78–4.11 < 0.001
Model 3
Age (per 10-year increase) 1.52 1.25–1.85 <0.001 1.23 1.02–1.49 0.029
HDL-C 0.53 0.23–1.24 0.145 0.42 0.18–0.97 0.041
EF (per 10% increase) 0.51 0.42–0.63 < 0.001 0.66 0.53–0.82 < 0.001
DD–/NLR– Ref – – Ref – –
DD–/NLR+ 3.31 1.70–6.43 < 0.001 2.76 1.40–5.40 0.003
DD+/NLR– 3.37 1.79–6.34 < 0.001 2.39 1.24–4.63 0.010
DD+/NLR+ 9.40 5.25–16.84 < 0.001 6.19 3.30–11.61 < 0.001
*Adjusted variables include age, body mass index, NLR, DD, HDL-C, estimated glomerular filtration rate, log peak cardiac troponin T,  
EF, three-vessel or left main disease; CI — confidence interval; DD — D-dimer; EF — ejection fraction; HDL-C — high-density lipoprotein  
cholesterol; HR — hazard ratio; NLR — neutrophil to lymphocyte ratio
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The mechanism by which elevated DD pre-
dicts adverse cardiovascular events is not yet 
fully understood. It has been documented that 
elevated DD levels reflect a more coagulable state, 
accelerate the progression of atherosclerotic le-
sions, and lead to unstable atherosclerotic plaque 
activity [20]. In addition, in the LIPID study and 
Speedwell study, it was found that DD is correlated 
to C-reactive protein, indicating that the level of 
DD may also reflect the state of inflammation 
[2, 19]. The mechanism may be that DD can medi-
ate and regulate the release of interleukin (IL)-6 
from monocytes [21]. IL-6 is an inflammatory factor 
and a clinical study has shown that inhibiting the 
IL-6 signaling pathway via a specific drug was asso-
ciated with a reduced risk of cardiovascular events 
and all-cause mortality in patients [22]. Therefore, 
we reasoned that baseline DD levels could reflect 
both thrombotic activity and inflammation, making 
it a good predictor. In the current study, baseline 
DD was an independent predictor of long-term 
MACEs in patients with ACS after PCI and had 
a comparable efficiency for differentiating MACEs 
to NLR. However, owing to the missing data on 
inflammation-related indicators, association be-
tween DD and inflammation could not be verified. 
Further research can be anticipated to expound on 
the relationship between the two. 
Neutrophil to lymphocyte ratio was calculated 
by dividing the neutrophil count by the lymphocyte 
count, which represents the dynamic balance of 
neutrophil and lymphocyte and reflects the inflam-
mation state of the body. Previous observational 
epidemiologic studies have described the relation-
ship between an elevated neutrophil count and 
increased cardiovascular risk in patients with stable 
angina and ACS [23, 24]. Neutrophil are involved in 
the progression of many aspects of cardiovascular 
pathophysiology, including atherosclerosis and 
thrombosis, eventually leading to ACS. There are 
three main mechanisms for how neutrophil medi-
ates atherosclerosis: (1) neutrophils can accumu-
late in atherosclerotic lesions and enhance plaque 
inflammation through degranulation of various 
proteins and enzymes, (2) neutrophils can recruit 
themselves, oxidize LDL-C, exacerbate endothelial 
cell dysfunction and cause plaque vulnerability by 
releasing reactive oxygen species, and (3) neutro-
phils contribute to plaque rupture by eroding the 
fibrous cap via proteinases and elastase. It was also 
reported that neutrophils can also activate coagu-
lation by releasing neutrophil extracellular traps 
[25]. Neutrophil extracellular traps then provide 
a hypercoagulable microenvironment, induce plate-
let activation, bind clotting factors and promote 
thrombosis [26].
Apart from neutrophils, lymphocytes also play 
an important role in the inflammatory reaction dur-
ing the atherosclerotic process. Low lymphocyte 
count has been demonstrated to be associated 
with increased risk of adverse events in various 
cardiovascular disease such as stable CHD, ACS 
and heart failure [23, 27, 28]. Experimental study 
revealed that increased lymphocytes apoptosis may 
be responsible for the association between low lym-
phocyte count and poor prognosis of cardiovascular 
diseases [29]. Apoptosis of lymphocytes that occurs 
in atherosclerotic lesions promotes atherosclerotic 
plaque growth, leads to lipid core development, 
and ultimately results in thrombotic events. Spon-
taneous lymphocyte apoptosis was found both in 
criminal plaque and peripheral blood, and it was 
more severe in ACS patients [30]. Therefore, by 
integrating neutrophil and lymphocyte counts si-
multaneously, NLR as an indicator of inflammation 
was found to have a more significant correlation 
in predicting long-term adverse cardiac outcomes 
in patients with ACS. In the present study, the 
incidence of MACEs was significantly higher in 
patients with elevated NLR, which is consistent 
with findings of previous studies [7, 8, 31]. It is also 
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Figure 3. Receiver operating characteristic curves for 
D-dimer (DD) and neutrophil to lymphocyte ratio (NLR) 
alone and DD in combination with NLR for predicting long-
term major adverse cardiovascular events; AUC — area 
under curve; *p < 0.05; NS — no significant difference.
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-associated hyperinflammation status in the body 
is related to MACEs, but inflammation caused by 
infectious diseases, such as influenza, has also been 
confirmed by clinical study to be related to acute 
myocardial infarction [32].
Additionally, it was found that older age, re-
duced EF and low HDL-C level were also associated 
with increased risks in patients with ACS undergo-
ing PCI. Advanced age and decreased EF are both 
known risk factors for increased mortality in patients 
with ACS. When it comes to HDL-C, a low level of 
HDL-C had been shown to be a good prognostic 
marker for predicting adverse cardiac events in 
patients with ACS [33]. In addition to the classic 
reverse cholesterol transport effect of HDL-C, re-
cent studies have shown that HDL-C can also exert 
antithrombotic effects and downregulate thrombin 
generation [34], as well as anti-inflammatory and 
regulating neutrophil function [35, 36]. Consistently, 
the current study showed that high HDL-C level 
was a protective factor in patients with ACS after 
PCI, and the combined value of DD and NLR for 
predicting MACEs was independent of HDL-C level.
Based on these predictive factors, survival 
models were further developed to predict MACEs 
in patients with ACS receiving PCI, which can 
quantify predictive factors for patients, help clini-
cians to assess prognosis as soon as possible and 
design appropriate strategies for each patient.
Limitations of the study
There are some limitations that need to be 
considered in the current study. First, the sample 
size was relatively small and was based on a single 
center, which might bring about selection bias. 
Second, in this retrospective study, 53 (7.5%) 
patients’ follow-up data were not available and 
the data collection might have missed some other 
important biomarkers such as C-reactive protein 
and B-type natriuretic peptide, so we were not able 
to investigate the relation between these markers 
and clinical outcomes, which may result in potential 
underpowering of some analyses. Third, we only 
compared the DD levels and NLR at admission, 
because data on the dynamic changes over time 
was limited. Considering the above-reported 
limitations, further prospective, well-designed and 
multicentric studies in larger scale are warranted 
to confirm the present findings. 
Conclusions
Admission DD and NLR are associated with 
long-term MACEs in ACS patients receiving PCI. 
The combination of the two may provide a more 
sensitive factor and help further optimize risk 
stratification and treatments in patients with ACS 
after PCI. 
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